Working Paper Article Version 1 This version is not peer-reviewed

Association of High Pre-Transplant Caveolin-1 Serum Concentrations with Attenuated Acute Cellular Rejection in Kidney Transplantation

Version 1 : Received: 29 November 2020 / Approved: 1 December 2020 / Online: 1 December 2020 (14:08:33 CET)

How to cite: Emmerich, F.; Zschiedrich, S.; Reichenbach-Braun, C.; Süsal, C.; Minguet, S.; Pauly, M.; Seidl, M. Association of High Pre-Transplant Caveolin-1 Serum Concentrations with Attenuated Acute Cellular Rejection in Kidney Transplantation. Preprints 2020, 2020120030 Emmerich, F.; Zschiedrich, S.; Reichenbach-Braun, C.; Süsal, C.; Minguet, S.; Pauly, M.; Seidl, M. Association of High Pre-Transplant Caveolin-1 Serum Concentrations with Attenuated Acute Cellular Rejection in Kidney Transplantation. Preprints 2020, 2020120030

Abstract

Acute and chronic transplant rejections due to alloreactivity are essential contributors to graft loss. However, the strength of alloreactivity is biased by non-immunological factors such as ischemia reperfusion injury (IRI). Accordingly, protection from IRI could be favorable in terms of limiting graft rejection. Caveolin-1 (Cav-1) is part of the cell membrane and an important regulator of intracellular signaling. Cav-1 has been demonstrated to limit IRI and to promote survival of a variety of cell types including renal cells under stress conditions. Accordingly, Cav-1 could also play a role in limiting anti-graft immune responses. Here, we evaluated a possible association between pretransplant serum concentrations of Cav-1 and the occurrence of rejection during follow up in a pilot study. Therefore, Cav-1-serum concentrations were analyzed in 91 patients at the time of kidney transplantation and compared to the incidence of acute and chronic rejection. Higher Cav-1 levels were associated with lower occurrence of acute rejection episodes. Moreover, Cav-1 could be therapeutically useful for attenuating graft rejection.

Keywords

Caveolin-1; kidney transplantation; graft rejection; ischemia; reperfusion injury (IRI)

Subject

Medicine and Pharmacology, Immunology and Allergy

Comments (0)

We encourage comments and feedback from a broad range of readers. See criteria for comments and our Diversity statement.

Leave a public comment
Send a private comment to the author(s)
* All users must log in before leaving a comment
Views 0
Downloads 0
Comments 0
Metrics 0


×
Alerts
Notify me about updates to this article or when a peer-reviewed version is published.
We use cookies on our website to ensure you get the best experience.
Read more about our cookies here.